Market Overview

UK To Import Columbia Care CBD Tablets For Clinical Study

UK To Import Columbia Care CBD Tablets For Clinical Study
Read more about our latest Cannabis News! CANNABIS HOME

Columbia Care Inc. (OTC: CCHWF) announced a collaboration Thursday with the pharma manufacturer IPS Specials.

The agreement will see Columbia Care’s BeneCeed CBD tablets imported into the United Kingdom for a clinical study.

Why It Matters

The agreement is the first step in Columbia Care's efforts to hold global clinical trials using its cannabis, the company said. 

BeneCeed will become the first approved cannabinoid investigational medicinal product imported from the U.S. by the U.K.’s Medicines and Healthcare products Regulatory Agency.

BeneCeed would be used in an examination of a late-stage Phase 2b trial.

Rosemary Mazanet, Columbia Care’s chief scientific officer, touched on the importance of the news in a statement.

“I am proud that we are now raising the bar once more with our funding and independent research partners as we move closer to reaching this momentous milestone for our company.”

IPS Specials has nearly two decades of experience facilitating the import of investigational medicinal products, Mazanet said. Columbia Care is also working with Grow Biotech, "a specialist in navigating challenging regulatory frameworks across the world," to coordinate the effort, she said. 

Columbia Care's stock was trading down 1.27% at $4.75 at the time of publication Thursday. 

Related Links:

Columbia Care Inc To Trade In US On The OTCQX Market

Columbia Care's Revenue Increases 45% Year-Over-Year; Cannabis MSO Opens Brooklyn, San Diego Dispensaries

Read more about our latest Cannabis News! CANNABIS HOME

Posted-In: CBD Grow Biotech IPS SpecialsCannabis News Markets


Related Articles (CCHWF)

View Comments and Join the Discussion!

Cannabis Movers

Sign up for our secret cannabis newsletter!
Never miss out on the breaking news in the Cannabis Industry!

Target's 'Transformational Quarter' Keeps Analysts Bullish On The Future

Edwards Lifesciences Shares Fall As FDA Reports Recall Of Sapien 3 Ultra